Table 2.
Definition | Total (n = 769), n (%) |
|
---|---|---|
Total women with primary outcome | 127 (16.5%) | |
Maternal death | Death during or within 42 days of delivery | 59 (7.7%) |
Maternal Morbidity | Occurrence of one or more of the defined organ support measures below | 97 (12.6%) |
Organ support | ||
Respiratory | Need for CPAP, BiPAP, or invasive ventilation | 73 |
Cardiovascular | Need for use of inotropes or vasopressors | 15 |
Renal | Renal replacement therapy for acute renal failure | 14 |
Hepatic | Liver transplantation. Other management of hepatic failure include ventilatory and circulatory support, management of elevated intracranial pressure and renal failure, medical therapies for hepatitis B virus (lamivudine); anticoagulation for Budd–Chiari syndrome. | 21 |
Hematological | Massive transfusion of at least 5 units of blood products | 60 |
Neurological | GCS score of less than 10 | 35 |
Uterine | Uncontrollable hemorrhage or infection leading to life-saving hysterectomy | 16 |
Abbreviations: BiPAP bilevel positive airway pressure, CPAP continuous positive airway pressure, GCS Glasgow Coma Scale
Maternal morbidities presented are not mutually exclusive and include those occurring in women who died. Morbidities have been grouped by organ system. All organ system outcomes required use of life-saving treatment for more than 7 days to meet outcome criteria with the exception of hematological and uterine support.